HPGDS is a novel prognostic marker associated with lipid metabolism and aggressiveness in lung adenocarcinoma

Fengling Shao; Huajie Mao; Tengling Luo; Qijun Li; Lei Xu; Yajun Xie

doi:10.3389/fonc.2022.894485

HPGDS is a novel prognostic marker associated with lipid metabolism and aggressiveness in lung adenocarcinoma

Front Oncol. 2022 Oct 17:12:894485. doi: 10.3389/fonc.2022.894485. eCollection 2022.

Authors

Fengling Shao¹, Huajie Mao², Tengling Luo³, Qijun Li³, Lei Xu³, Yajun Xie¹

Affiliations

¹ The Ministry of Education Key Laboratory of Laboratory Medical Diagnostics, The College of Laboratory Medicine, Chongqing Medical University, Chongqing, China.
² Department of Laboratory Medicine, The First Hospital of Xi'an, Xi'an, China.
³ Laboratory Animal Center, Chongqing Medical University, Chongqing, China.

Abstract

Background: Lung adenocarcinoma (LUAD) is the most common respiratory globallywith a poor prognosis. Lipid metabolism is extremely important for the occurrence and development of cancer. However, the role of genes involved in lipid metabolism in LUAD development is unclear. We aimed to identify the abnormal lipid metabolism pathway of LUAD, construct a novel prognostic model of LUAD, and discover novel biomarkers involved in lipid metabolism in LUAD.

Methods: Based on differentially expressed genes involved in lipid metabolism in LUAD samples from The Cancer Genome Atlas (TCGA), abnormal lipid metabolism pathways in LUAD were analyzed. The lasso penalized regression analysis was performed on the TCGA cohort (training set) to construct a risk score formula. The predictive ability of the risk score was validated in the Gene Expression Omnibus (GEO) dataset (validation set) using Kaplan-Meier analysis and ROC curves. Finally, based on CRISPR gene editing technology, hematopoietic prostaglandin D synthase (HPGDS) was knocked out in A549 cell lines, the changes in lipid metabolism-related markers were detected by western blotting, and the changes in cell migration were detected by transwell assay.

Results: Based on the differential genes between lung cancer tissue and normal tissue, we found that the arachidonic acid metabolism pathway is an abnormal lipid metabolism pathway in both lung adenocarcinoma and lung squamous cell carcinoma. Based on the sample information of TCGA and abnormally expressed lipid metabolism-related genes, a 9-gene prognostic risk score was successfully constructed and validated in the GEO dataset. Finally, we found that knockdown of HPGDS in A549 cell lines promoted lipid synthesis and is more invasive than in control cells. Rescue assays showed that ACSL1 knockdown reversed the pro-migration effects of HPGDS knockdown. The knockdown of HPGDS promoted migration response by upregulating the expression of the lipid metabolism key enzymes ACSL1 and ACC.

Conclusion: The genes involved in lipid metabolism are associated with the occurrence and development of LUAD. HPGDS can be a therapeutic target of a potential lipid metabolism pathway in LUAD, and the therapeutic target of lipid metabolism genes in LUAD should be studied further.

Keywords: bioinformatics; biomarkers; hPGDS; lipid metabolism; lung adenocarcinoma.